EUNICE NSOFOR: Open Payments
NPI 1821577354 · MANSFIELD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,331 in 38 payments from 8 companies in 2025. Trend: 2023 $627 · 2024 $775 · 2025 $1,331
Food & beverage: $1,331
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $438 |
| Janssen Pharmaceuticals, Inc | 3 | $216 |
| Supernus Pharmaceuticals, Inc. | 18 | $159 |
| Otsuka America Pharmaceutical, Inc. | 3 | $153 |
| E.R. Squibb & Sons, L.L.C. | 2 | $145 |
| Teva Pharmaceuticals USA, Inc. | 1 | $140 |
| ABBVIE INC. | 4 | $65 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: CAPLYTA, INVEGA SUSTENNA, Qelbree, REXULTI, COBENFY, AUSTEDO XR, VRAYLAR, Auvelity.
Industry payments across TX — which companies pay providers there.
